Drug intelligence / Profile preview

clarenicol

Development stage: Preclinical
Lead developer: PegBio
Administration: Oral

Overview

Clarenicol is an oral liquid developed by Guangzhou Wanglaoji Pharmaceutical Co. LTD, a company known for traditional Chinese medicine and herbal products. It is being investigated for its relieving effect on throat symptoms associated with novel coronavirus pneumonia (COVID-19) in convalescence, suspected patients, and other susceptible individuals. The intervention involves oral administration of 20ml, three times a day for seven days, with observation for 14 days. Its specific mechanism of action is not detailed, but it is presumed to act through properties commonly found in traditional herbal remedies for symptomatic relief.

Other names: Clarenicol oral liquid

Beyond the preview

Go deeper on clarenicol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on clarenicol.

Explore the full profile